|Mr. Adrian Rawcliffe||CFO, CEO, Principal Accounting Officer & Director||678.6k||1.03M||1972|
|Dr. Helen Katrina Tayton-Martin||Co-Founder & Chief Bus. Officer||549.52k||N/A||1967|
|Mr. William C. Bertrand Jr.||Chief Operating Officer||608.52k||N/A||1965|
|Dr. Rafael G. Amado||Pres of R&D||710.14k||N/A||1964|
|Mr. Sébastien Desprez||VP of Communications & Investor Relations||N/A||N/A||N/A|
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.